Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer-Reference-Cited by-同舟云学术

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Published:2021-12 Issue:3 Volume:163 Page:490-497
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Swisher Elizabeth M.,Kristeleit Rebecca S.,Oza Amit M.,Tinker Anna V.,Ray-Coquard Isabelle,Oaknin Ana,Coleman Robert L.,Burris Howard A.,Aghajanian Carol,O'Malley David M.,Leary Alexandra,Welch Stephen,Provencher Diane,Shapiro Geoffrey I.,Chen Lee-may,Shapira-Frommer Ronnie,Kaufmann Scott H.,Goble Sandra,Maloney Lara,Kwan Tanya,Lin Kevin K.,McNeish Iain A.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference23 articles.

1. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase;Bryant;Nature.,2005

2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature.,2005

3. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety;Kristeleit;Int. J. Gynecol. Cancer,2019

4. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2;Oza;Gynecol. Oncol.,2017

5. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial;Swisher;Lancet Oncol.,2017

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib;Diagnostics;2024-08-29

2. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers;British Journal of Cancer;2024-07-06

3. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer;Annals of Oncology;2024-04

4. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer;Cancer;2024-01-30

5. PARP inhibitors in non-ovarian gynecologic cancers;Therapeutic Advances in Medical Oncology;2024-01